The rapid expansion of glucagon-like peptide-1 receptor agonists for weight management is restructuring corporate health plan expenditures. Employers are attempting to balance employee wellness retention benefits against compound double-digit spending increases in pharmacy benefits.
Benefit Design Adjustments
Third-party administrators report that over 35% of self-insured employer plans have implemented prior-authorization restrictions or mandatory lifestyle management programs before approving coverage. These measures aim to curtail off-label spending.
Long-Term Claims Offset
Actuarial projections indicate that while immediate pharmacy costs rise, downstream claims related to cardiovascular events and type 2 diabetes management may decrease over a five-to-seven-year period, creating a complex return-on-investment timeline for benefit directors.